The monoclonal antibodies market would grow at a CAGR of 11.8% over the predicted time frame. The market is expected to increase in value from US$ 186.6 Bn in 2022 to US$ 566.72 Bn in 2030.
The on monoclonal
antibodies Market, which provides a business strategy, research &
development activities, concise outline of the market valuation, valuable
insights pertaining to market share, size, supply chain analysis, competitive
landscape and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1735
Report Scope of the Monoclonal Antibodies Market
| Report Coverage | Details |
| Market Size by 2032 | USD 566.72 Billion |
| Market Size in 2023 | USD 207.68 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.8% |
| North America Market Share in 2022 | 46% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Source, Indication, Distribution Channel, Production Methods, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Monoclonal antibodies Market. The report provides a
comprehensive analysis of key factors that are expected to drive the growth of
this market. This study also provides a detailed overview of the opportunities
along with the current trends observed in the Monoclonal antibodies market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Monoclonal antibodies
market are included as given below:
Monoclonal antibodies Market Key Players
- Johnson & Johnson
- Merck
- AbbVie
- Amgen
- GlaxoSmithKline plc.
- Norvatis AG
- Pfizer Inc.
- Thermofischer Scientific
- Elililly and Company
- Bristol-Myers Squibb
Market Segments
- Humanized mAb
- Human mAb
- Murine mAb
- Chimeric mAb
By Indication
- Cancer
- Breast cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Others
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Others
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Production Methods
- In Vivo
- In Vitro
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global monoclonal
antibodies market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the monoclonal
antibodies market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Monoclonal Antibodies Market
5.1. COVID-19 Landscape: Monoclonal Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Monoclonal Antibodies Market, By Source
8.1. Monoclonal Antibodies Market, by Source, 2022-2030
8.1.1. Humanized mAb
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Human mAb
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Murine mAb
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Chimeric mAb
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Monoclonal Antibodies Market, By Indication
9.1. Ambulatory Surgical Center Market, by Indication e, 2022-2030
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Autoimmune Diseases
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inflammatory Diseases
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Monoclonal Antibodies Market, By Distribution Channel
10.1. Monoclonal Antibodies Market, by Distribution Channel, 2022-2030
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Online Pharmacy
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Retail Pharmacy
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Monoclonal Antibodies Market, By Production Methods
11.1. Monoclonal Antibodies Market, by Production Methods, 2022-2030
11.1.1. In Vivo
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. In Vitro
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Monoclonal Antibodies Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Source (2017-2030)
12.1.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Source (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Source (2017-2030)
12.2.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Source (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Source (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Source (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Source (2017-2030)
12.3.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Source (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Source (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Source (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Source (2017-2030)
12.4.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Source (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Source (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Source (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Source (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Production Methods (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Source (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Production Methods (2017-2030)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. AbbVie
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Amgen
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Norvatis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Thermofischer Scientific
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Elililly and Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Bristol-Myers Squibb
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments